Nodality develops biologically-informed clinical treatments for patients with cancer and autoimmune diseases.
Nodality, Inc., a biotechnology company, discovers and develops personal diagnostics characterizing cell signaling pathways in defined cellular sub-populations of malignant and normal cells from individual patients. The company focuses on hematological malignancies and autoimmune disorders. Nodality, Inc. was incorporated in 2003 and is based in San Francisco, California with an additional office in Franklin, Tennessee.
Announced Date | Round | Money Raised | Number of Investors | Lead Investors | Post Valuation | |
---|---|---|---|---|---|---|
Aug 17, 2006 | Series A | $1.54M | 1 | — | — | Detail |